Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study
The current first-line standard treatment for advanced small cell lung cancer (SCLC) is a combination of chemotherapy and immunotherapy. However, few efficacy data are available in a real-life settings, including frail patients. The aim of this study is to describe the real-life efficacy of chemoimm...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-09-01
|
| Series: | Cancers |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2072-6694/15/18/4593 |
| _version_ | 1797580851552190464 |
|---|---|
| author | Rémy Ezzedine Anthony Canellas Charles Naltet Marie Wislez Reza Azarian Andrei Seferian Etienne Giroux Leprieur |
| author_facet | Rémy Ezzedine Anthony Canellas Charles Naltet Marie Wislez Reza Azarian Andrei Seferian Etienne Giroux Leprieur |
| author_sort | Rémy Ezzedine |
| collection | DOAJ |
| description | The current first-line standard treatment for advanced small cell lung cancer (SCLC) is a combination of chemotherapy and immunotherapy. However, few efficacy data are available in a real-life settings, including frail patients. The aim of this study is to describe the real-life efficacy of chemoimmunotherapy in an unselected SCLC population. We conducted a retrospective multicenter study, which compared two cohorts of patients with treatment-naive metastatic SCLC treated in six academic centers in the Greater Paris area. Cohort 1 included patients treated with chemotherapy between January 2017 and December 2018, and cohort 2 included patients treated with chemoimmunotherapy between January 2019 and December 2020. A total of 153 consecutive patients were included (cohort 1: n = 96; cohort 2: n = 57). Clinical characteristics were similar between the two cohorts. Overall survival (OS) was statistically higher in cohort 2 (median survival 15.47 months) than in cohort 1 (median survival 9.5 months) (p = 0.0001). OS for patients with a performance status ≥2 and for patients ≥70 years old was not statistically different between the two cohorts. Chemoimmunotherapy efficacy was better compared to chemotherapy alone in case of brain or liver metastases. In conclusion, the combination of chemoimmunotherapy in metastatic SCLC appears to provide a real-life OS benefit. Dedicated clinical trials are needed to test this strategy in patients with impaired performance status or advanced age. |
| first_indexed | 2024-03-10T22:56:52Z |
| format | Article |
| id | doaj.art-06c8b961eb5d400bb447084b5a806ce0 |
| institution | Directory Open Access Journal |
| issn | 2072-6694 |
| language | English |
| last_indexed | 2024-03-10T22:56:52Z |
| publishDate | 2023-09-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cancers |
| spelling | doaj.art-06c8b961eb5d400bb447084b5a806ce02023-11-19T09:55:58ZengMDPI AGCancers2072-66942023-09-011518459310.3390/cancers15184593Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control StudyRémy Ezzedine0Anthony Canellas1Charles Naltet2Marie Wislez3Reza Azarian4Andrei Seferian5Etienne Giroux Leprieur6Department of Respiratory Diseases and Thoracic Oncology, APHP—Hôpital Ambroise Paré, 92104 Boulogne-Billancourt, FranceDepartment of Respiratory Diseases and Thoracic Oncology, APHP—Hôpital Tenon, 75020 Paris, FranceDepartment of Respiratory Diseases, Hôpital Paris Saint Joseph, 75014 Paris, FranceThoracic Oncology Unit, Pulmonology Department, APHP—Hôpital Cochin, Université Paris Cité, 75006 Paris, FranceDepartment of Respiratory Diseases, Hôpital Mignot, 78150 Le Chesnay, FranceDepartment of Respiratory Diseases, APHP—Hôpital Bicêtre, 94270 Le Kremlin-Bicêtre, FranceDepartment of Respiratory Diseases and Thoracic Oncology, APHP—Hôpital Ambroise Paré, 92104 Boulogne-Billancourt, FranceThe current first-line standard treatment for advanced small cell lung cancer (SCLC) is a combination of chemotherapy and immunotherapy. However, few efficacy data are available in a real-life settings, including frail patients. The aim of this study is to describe the real-life efficacy of chemoimmunotherapy in an unselected SCLC population. We conducted a retrospective multicenter study, which compared two cohorts of patients with treatment-naive metastatic SCLC treated in six academic centers in the Greater Paris area. Cohort 1 included patients treated with chemotherapy between January 2017 and December 2018, and cohort 2 included patients treated with chemoimmunotherapy between January 2019 and December 2020. A total of 153 consecutive patients were included (cohort 1: n = 96; cohort 2: n = 57). Clinical characteristics were similar between the two cohorts. Overall survival (OS) was statistically higher in cohort 2 (median survival 15.47 months) than in cohort 1 (median survival 9.5 months) (p = 0.0001). OS for patients with a performance status ≥2 and for patients ≥70 years old was not statistically different between the two cohorts. Chemoimmunotherapy efficacy was better compared to chemotherapy alone in case of brain or liver metastases. In conclusion, the combination of chemoimmunotherapy in metastatic SCLC appears to provide a real-life OS benefit. Dedicated clinical trials are needed to test this strategy in patients with impaired performance status or advanced age.https://www.mdpi.com/2072-6694/15/18/4593small-cell lung canceratezolizumabbrain metastasesliver metastaseselderly |
| spellingShingle | Rémy Ezzedine Anthony Canellas Charles Naltet Marie Wislez Reza Azarian Andrei Seferian Etienne Giroux Leprieur Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study Cancers small-cell lung cancer atezolizumab brain metastases liver metastases elderly |
| title | Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study |
| title_full | Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study |
| title_fullStr | Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study |
| title_full_unstemmed | Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study |
| title_short | Evaluation of Real-Life Chemoimmunotherapy Combination in Patients with Metastatic Small Cell Lung Carcinoma (SCLC): A Multicentric Case–Control Study |
| title_sort | evaluation of real life chemoimmunotherapy combination in patients with metastatic small cell lung carcinoma sclc a multicentric case control study |
| topic | small-cell lung cancer atezolizumab brain metastases liver metastases elderly |
| url | https://www.mdpi.com/2072-6694/15/18/4593 |
| work_keys_str_mv | AT remyezzedine evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT anthonycanellas evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT charlesnaltet evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT mariewislez evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT rezaazarian evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT andreiseferian evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy AT etiennegirouxleprieur evaluationofreallifechemoimmunotherapycombinationinpatientswithmetastaticsmallcelllungcarcinomasclcamulticentriccasecontrolstudy |